Ascensia Diabetes Care Announces Global Partnership With POCTech to Distribute and Co-develop Continuous Glucose Monitoring Systems

Food and Healthcare Press Releases Tuesday January 8, 2019 13:03
BASEL, Switzerland--8 Jan--PRNewswire/InfoQuest
Ascensia Diabetes Care today announced it has entered into a global alliance with Zhejiang POCTech, Co., Ltd (POCTech), a developer and manufacturer of continuous glucose monitoring (CGM) systems.
(Logo: https://mma.prnewswire.com/media/749389/Ascensia_Diabetes_Care_Logo.jpg )

Ascensia has entered into an agreement that appoints them as the exclusive distributor for POCTech in an initial 13 specifically selected markets where POCTech does not yet have a distributor, with the right of first refusal for distribution rights in other available countries. As part of this agreement Ascensia will commercialize a version of POCTech's current CGM product in these geographies and is intending to begin distributing product in the second half of 2019.

As the second part of this alliance, Ascensia and POCTech have also entered into a joint development agreement to co-develop next-generation products that build on POCTech's existing technology. This agreement will leverage expertise from both companies to build and manufacture exciting next-generation products with enhanced capabilities and features that are designed to more effectively meet the needs of people with diabetes.

"We are committed to expanding our business beyond blood glucose monitoring and we see continuous glucose monitoring as a critical component of diabetes care. This partnership will enable us to bring an approved CGM product to selected markets in 2019 and at the same time create novel CGM systems that build on POCTech's existing technology to address some of the unmet needs of people with diabetes," said Michael Kloss, CEO, Ascensia Diabetes Care.

Yanan Zhang, Ph.D., President and Chief Scientific Officer of Zhejiang POCTech, Co., Ltd, commented: "The collaboration between the two companies is an important milestone to the goal of reaching out to the worldwide market as well as creating our next generation CGM products. By combining Ascensia's strength in global marketing, regulatory affairs, quality systems, and capabilities for designing and testing new systems, with POCTech's expertise in sensor technology, we will together be able to provide the diabetes community with high quality and cost effective products."

Michael added, "This agreement with POCTech is the key first step in building a world-class CGM franchise for Ascensia. We are aiming to use a combination of partnerships and our own in-house CGM development program to build a pipeline of state-of-the-art CGM products that improve on what is currently available for people with diabetes."

Ascensia has a long heritage in diabetes care and this co-development agreement will leverage its in-house expertise and capabilities in developing and commercializing diabetes technologies. The partnership will also leverage the world class manufacturing expertise of sister company, PHC Corporation, who manufacture the CONTOUR portfolio of meters and sensors.

Ascensia's extensive R&D experience in this area has led to the introduction of many user centered innovations in diabetes, such as No-Coding technology and Second Chance sampling. Ascensia is responsible for the development of the remarkably accurate CONTOUR NEXT test strip platform and hopes to apply their expertise in sensor development to the next generation of CGM systems through this collaboration.

For further information, please visit the Ascensia Diabetes Care website at: http://www.ascensia.com
Ascensia and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings.
For more information about Zhejiang POCTech Co. Ltd., please visit the POCTech website: http://www.poctechcorp.com/en/
Source: Ascensia Diabetes Care

Latest Press Release

Mallinckrodt Announces Interim Analysis Results for Therakos(R) Platform Phase 3 Clinical Trial in Treatment of Pediatric Patients with Steroid Refractory Acute Graft-versus-Host Disease

-- Overall response rate exceeded specified study midpoint target (n=25); company elects to discontinue further patient enrollment as allowed by protocol -- Mallinckrodt plc (NYSE:MNK), a leading global specialty pharmaceutical company, today announced...

Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey

- Global Commission's recommendations focus on three solution pathways that leverage technology to address key elements of the rare disease diagnostic odyssey - Rare diseases remain undiagnosed as patients struggle to navigate complex health systems to...

Pivotal Phase III Data for BAVENCIO(R) (avelumab) Plus INLYTA(R) (axitinib) in Advanced Renal Cell Carcinoma Published in the New England Journal of Medicine

- JAVELIN Renal 101 shows significant improvement in progression-free survival with a hazard ratio of 0.69 in patients regardless of PD-L1 expression - US FDA has granted Priority Review to BAVENCIO plus INLYTA for patients with advanced renal cell...

ISABS เตรียมจัดการประชุมว่าด้วยการแพทย์ส่วนบุคคลที่โครเอเชีย พร้อมเชิญเจ้าของรางวัลโนเบลร่วมบรรยาย

International Society for Applied Biological Sciences (ISABS) ร่วมกับ Mayo Clinic และ St. Catherine Hospital เตรียมจัดการประชุม "ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine" ครั้งที่ 11...

ISABS: Personalized Medicine Conference With Nobel Laureates to Be Held in Split, Croatia

International Society for Applied Biological Sciences (ISABS), Mayo Clinic and St. Catherine Hospital are organizing "11th ISABS Conference on Forensic and Anthropologic Genetics and Mayo Clinic Lectures in Individualized Medicine"(http://www.isabs.net)...

Related Topics